Ruriko Tanaka

894 citations

23 papers · 727 indexed · h-index 14

Co-authors: Shinya Kimura Eishi Ashihara Taira Maekawa Asumi Yokota Miki Takeuchi Yoko Ueno Masamichi Mori Rika Saito
Topics: Chronic Myeloid Leukemia Treatments (15 papers)Chronic Lymphocytic Leukemia Research (8 papers)Eosinophilic Disorders and Syndromes (6 papers)
Cited by: Hematology Genetics Oncology
Journals: Journal of Clinical Oncology Blood Cancer Research
Partner nations: Japan United States Australia

In The Last Decade

Ruriko Tanaka

23 papers receiving 711 citations

Peers

Countries citing papers authored by Ruriko Tanaka

Since Specialization

Citations

This map shows the geographic impact of Ruriko Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruriko Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruriko Tanaka more than expected).

Fields of papers citing papers by Ruriko Tanaka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruriko Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruriko Tanaka. The network helps show where Ruriko Tanaka may publish in the future.

Co-authorship network of co-authors of Ruriko Tanaka

This figure shows the co-authorship network connecting the top 25 collaborators of Ruriko Tanaka. A scholar is included among the top collaborators of Ruriko Tanaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruriko Tanaka. Ruriko Tanaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia 2017 ·Investigational New Drugs ·Masamichi Mori,Naoki Kaneko,Yoko Ueno,Masaki Yamada,Ruriko Tanaka,Rika Saito,Itsuro Shimada,Kenichi Mori,Sadao Kuromitsu	200
2	ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML). 2014 ·Journal of Clinical Oncology ·Masamichi Mori,Naoki Kaneko,Yoko Ueno,Ruriko Tanaka,(unknown),Rika Saito,(unknown),Itsuro Shimada,Sadao Kuromitsu	24
3	Abstract 866: ASP3026, a selective ALK inhibitor, induces tumor regression in a crizotinib-refractory model and prolongs survival in an intrapleurally xenograft model 2012 ·Cancer Research ·Masamichi Mori,Sadao Kuromitsu,Yoko Ueno,Ruriko Tanaka,Itsuro Shimada,(unknown),(unknown),Hideki Sakagami,Hiroshi Fushiki,Rika Saito,Takanori Sengoku	7
4	Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients 2011 ·Cancer Letters ·Ruriko Tanaka,Shinya Kimura,Eishi Ashihara,Mariko Yoshimura,Naoto Takahashi,Hisashi Wakita,Kuniaki Itoh,Kaichi Nishiwaki,Kenshi Suzuki,Rina Nagao,Hisayuki Yao,Yoshihiro Hayashi,(unknown),Hideyo Hirai,Ken-ichi Sawada,Oliver G. Ottmann,Junia V. Melo,Taira Maekawa	15
5	Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65 – a novel Wnt/β-catenin signaling inhibitor 2011 ·Cancer Letters ·Rina Nagao,Eishi Ashihara,Shinya Kimura,Jeffrey Strovel,Hisayuki Yao,Miki Takeuchi,Ruriko Tanaka,Yoshihiro Hayashi,Hideyo Hirai,Janak Padia,(unknown),Taira Maekawa	18
6	A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro 2010 ·Cancer Letters ·(unknown),Eishi Ashihara,Yoko Nakagawa,Takahiro Kiuchi,(unknown),Hisayuki Yao,(unknown),Ruriko Tanaka,Rina Nagao,Asumi Yokota,Miki Takeuchi,Shinya Kimura,Hideyo Hirai,Taira Maekawa	13
7	Galectin‐9 ameliorates acute GVH disease through the induction of T‐cell apoptosis 2010 ·European Journal of Immunology ·(unknown),Eri Kawata,Eishi Ashihara,Yoko Nakagawa,Akira Yamauchi,Hisayuki Yao,Rina Nagao,Ruriko Tanaka,Asumi Yokota,Miki Takeuchi,Hideyo Hirai,Shinya Kimura,Mitsuomi Hirashima,Norio Yoshimura,Taira Maekawa	40
8	Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr‐Abl positive leukemic cells 2010 ·Cancer Science ·Miki Takeuchi,Eishi Ashihara,Yohko Yamazaki,Shinya Kimura,Yoko Nakagawa,Ruriko Tanaka,Hisayuki Yao,Rina Nagao,Yoshihiro Hayashi,Hideyo Hirai,Taira Maekawa	33
9	Osteoclasts are involved in the maintenance of dormant leukemic cells 2009 ·Leukemia Research ·Asumi Yokota,Shinya Kimura,Ruriko Tanaka,Miki Takeuchi,Hisayuki Yao,(unknown),Rina Nagao,Junya Kuroda,Yuri Kamitsuji,Eri Kawata,Eishi Ashihara,Taira Maekawa	14
10	Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors. 2009 ·Blood ·Miki Takeuchi,Shinya Kimura,Junya Kuroda,Eishi Ashihara,Makoto Kawatani,Hiroyuki Osada,Kazuo Umezawa,(unknown),Masaya Imoto,Takashi Tsuruo,Asumi Yokota,Ruriko Tanaka,Rina Nagao,Tatsutoshi Nakahata,Yoshihide Fujiyama,Taira Maekawa	3
11	Osteoclasts Are Involved in the Maintenance of Dormant Leukemic Cells. 2009 ·Blood ·Asumi Yokota,Shinya Kimura,Ruriko Tanaka,Miki Takeuchi,Hisayuki Yao,(unknown),Rina Nagao,Eishi Ashihara,Taira Maekawa	1
12	Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer 2008 ·Molecular Cancer Therapeutics ·(unknown),Eishi Ashihara,Shinya Kimura,Kazumasa Takenaka,Kiyoshi Sato,Ruriko Tanaka,Asumi Yokota,Yuri Kamitsuji,Miki Takeuchi,Junya Kuroda,Fumihiro Tanaka,Toshikazu Yoshikawa,Taira Maekawa	47
13	JAK2V617F-Positive Essential Thrombocythemia and Multiple Myeloma with IGH/CCND1 Gene Translocation Coexist, but Originate from Separate Clones 2008 ·Acta Haematologica ·Junya Kuroda,Yosuke Matsumoto,Ruriko Tanaka,(unknown),Tsutomu Kobayashi,Daisuke Shimizu,Shinya Kimura,Eishi Ashihara,Shigeo Horiike,Chihiro Shimazaki,Masafumi Taniwaki	11
14	Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and β-catenin 2008 ·International Journal of Hematology ·Junya Kuroda,Yuri Kamitsuji,Shinya Kimura,Eishi Ashihara,Eri Kawata,Yoko Nakagawa,(unknown),(unknown),Asumi Yokota,Ruriko Tanaka,Michael Andreeff,Masafumi Taniwaki,Taira Maekawa	48
15	Abl tyrosine kinase inhibitors for overriding Bcr–Abl/T315I: from the second to third generation 2008 ·Expert Review of Anticancer Therapy ·Ruriko Tanaka,Shinya Kimura	34
16	Fully automated and super-rapid system for the detection of JAK2V617F mutation 2008 ·Leukemia Research ·Ruriko Tanaka,Junya Kuroda,William Stevenson,Eishi Ashihara,Takayuki Ishikawa,Tomohiko Taki,Yutaka Kobayashi,Yuri Kamitsuji,Eri Kawata,Miki Takeuchi,(unknown),Asumi Yokota,Mitsuharu Hirai,(unknown),Masafumi Taniwaki,Taira Maekawa,Shinya Kimura	26
17	A Novel β-catenin Inhibitor, AV65 Suppresses the Growth of CML Cell Lines Which Acquire Imatinib-Resistance Because of Abl Kinase Domain Mutations Including T315I and Hypoxia-Adaptation. 2008 ·Blood ·Rina Nagao,Shinya Kimura,Eishi Ashihara,Miki Takeuchi,Ruriko Tanaka,Asumi Yokota,Hisayuki Yao,Jeffrey Strovel,Wieslaw M. Cholody,Taira Maekawa	3
18	Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models. 2008 ·Blood ·Ruriko Tanaka,Matthew Squires,Shinya Kimura,Asumi Yokota,Kirsty Mallett,Tomoko Smyth,Neil T. Thompson,Rina Nagao,Takahiro Yamauchi,Takashi Ushiki,John F. Lyons,Taira Maekawa	6
19	Roles of Osteoclasts in Leukemic Cells 2008 ·Blood ·Asumi Yokota,Shinya Kimura,Ruriko Tanaka,Rina Nagao,(unknown),Hisayuki Yao,Miki Takeuchi,Makoto Kawatani,Hiroyuki Osada,Eishi Ashihara,Taira Maekawa	1
20	ABT‐737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug‐resistance mechanisms 2007 ·British Journal of Haematology ·Junya Kuroda,Shinya Kimura,Michael Andreeff,Eishi Ashihara,Yuri Kamitsuji,Asumi Yokota,Eri Kawata,Miki Takeuchi,Ruriko Tanaka,(unknown),Yosuke Matsumoto,Hideo Tanaka,Andreas Strasser,Masafumi Taniwaki,Taira Maekawa	70

About Ruriko Tanaka

Ruriko Tanaka is a scholar working on Hematology, Genetics and Rheumatology, having authored 23 papers that have together received 727 indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Eosinophilic Disorders and Syndromes (6 papers). The work is most often cited by research in Hematology (346 citations), Genetics (199 citations) and Oncology (159 citations). Ruriko Tanaka has collaborated with scholars based in Japan, United States and Australia. Frequent co-authors include Shinya Kimura, Eishi Ashihara, Taira Maekawa, Asumi Yokota, Miki Takeuchi, Yoko Ueno, Masamichi Mori, Rika Saito, Sadao Kuromitsu and Itsuro Shimada. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact